COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL NZNZ COCO BUBU More..
Favipiravir study #1 of 12
3/18 Late treatment study
Cai et al., Engineering, doi:10.1016/j.eng.2020.03.007 (Peer Reviewed)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Source   PDF   Share   Tweet
Comparison of 35 FPV patients and 35 LPV/RTV patients, showing significant improvements in chest CT and faster viral clearance with FPV.

Cai et al., 3/18/2020, retrospective, China, Asia, peer-reviewed, 26 authors.
risk of no improvement in CT, 68.7% lower, RR 0.31, p = 0.04, treatment 35, control 45, multivariate.
risk of no virological cure, 70.9% lower, RR 0.29, p = 0.03, treatment 35, control 45, multivariate.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 12 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.